-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in infants, and researchers recently examined the effects of a single Nirsevimab monoimmune injection on the risk of infection in infants throughout the RSV epidemic season.
the study, the researchers assessed the effects of Nirsevimab on RSV-related lower respiratory tract infections in premature and healthy newborns (29 weeks to 34 weeks 6 days).
before the start of the RSV epidemic season, the study involved newborns receiving a single intramuscular injection of 50 mg of Nirsevimab or a placebo. The main endpoint of the
study was a 150-day medical intervention for RSV-related lower respiratory tract infections.
secondary efficacy endpoint was 150 days of hospitalization for RSV-related lower respiratory tract infections.
from November 2016 to November 2017, a total of 1,453 infants participated in the study and received Eirsevimab (n-969) or a placebo (n?484) before the RSV pandemic.
statistics found that the incidence of RSV-related lower respiratory tract infections requiring internal medicine in the Nirsevimab group was 70.1% lower than in the placebo group (2.6% vs 9.5%).
the hospitalization rate of RSV-related lower respiratory tract infections after preventive treatment in Nirsevimab decreased by 78.4% (0.8% vs 4.1%, P-lt;0.001) compared to the placebo group.
had similar adverse reactions between the groups and had no apparent allergic reactions.
single injection of Nirsevimab throughout the RSV epidemic season reduces the risk of RSV-related respiratory infections and hospitalization in healthy premature infants.
.